Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,728 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,728 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the completion of the sale, the chief executive officer now directly owns 185,034 shares in the company, valued at $27,090,827.94. This trade represents a 2.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $468,111.60.
• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The stock was sold at an average price of $120.76, for a total transaction of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The stock was sold at an average price of $130.40, for a total value of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total value of $645,483.52.

Natera Trading Down 3.3 %

NASDAQ:NTRA opened at $146.06 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. The business’s 50-day simple moving average is $127.38 and its 200-day simple moving average is $115.46. Natera, Inc. has a fifty-two week low of $52.01 and a fifty-two week high of $167.79. The stock has a market capitalization of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. Sell-side analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NTRA. Craig Hallum raised their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday. The Goldman Sachs Group boosted their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Piper Sandler restated an “overweight” rating and set a $150.00 target price on shares of Natera in a research report on Friday, September 13th. Finally, Sanford C. Bernstein raised their price target on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $137.65.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new position in shares of Natera in the second quarter valued at $28,000. Quarry LP grew its holdings in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC increased its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the last quarter. Covestor Ltd lifted its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Natera during the 3rd quarter worth about $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.